Mira Pharmaceuticals (MIRA) Receivables (2023 - 2024)
Mira Pharmaceuticals (MIRA) posted Receivables of $5000.0 for Q4 2024, down 70.35% sequentially from $16862.0 in Q4 2023, and down 70.35% YoY from $16862.0 in Q1 2024.
Mira Pharmaceuticals (MIRA) Receivables (2023 - 2024) Analysis & Trends
Mira Pharmaceuticals has reported Receivables for 2 years, with the latest figure at $5000.0 in Q4 2024.
- Quarterly Receivables fell 70.35% year-over-year to $5000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $5000.0 (down 70.35% YoY) and the FY2024 annual result came in at $40439.0, up 139.82% from the prior year.
- Receivables eased to $5000.0 in Q4 2024 per MIRA's latest filing, from $16862.0 in the prior quarter.
- Over five years, Receivables peaked at $16862.0 in Q4 2023 and troughed at $5000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 16,862.00 |